Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Sunday, December 21 2014 5:04am ET - U.S. Markets Closed.
Industry Center
Industry Center > > Genentech, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Genentech, Inc. Company Profile
"The few, the proud, the profitable" could be Genentech's motto. One of the world's oldest and most successful biotechs (in an industry full of money-losers), the firm has a number of blockbuster cancer therapies based on its antibody (protein) technologies. Its oncology portfolio contains Rituxan (non-Hodgkin's lymphoma), Avastin (colorectal and lung cancers), Herceptin (breast cancer), Tarceva (lung cancer), Xeloda (metastatic colorectal cancer), and Zelboraf (inoperable melanoma). Other marketed drugs include age-related macular degeneration treatment Lucentis, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Genentech is wholly owned by Swiss pharma powerhouse Roche.
Headlines for Genentech, Inc.
Roche's Genentech defends supply shift for top cancer drugs
- Mon Nov 24
Roche says head of Genentech research unit to retire
- Fri Dec 12
Roche biotech unit submits skin cancer drug application to U.S. regulator
- Mon Dec 15
AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised)
- Wed Dec 10
AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH
- Mon Dec 8
US/Global Policymakers Urged to Accelerate Cancer Research, Biomedical Discovery
- Mon Dec 8
Contact Information
Address: 1 DNA Way
South San Francisco, CA 94080-4990
Phone:650-225-1000
Fax:650-225-6000
Financial Highlights
Fiscal Year End:December
Key People
EVP Research and Early Development Center: Richard Scheller
VP Government Affairs: Walter K. Moore
SVP Procurement and Contract Manufacturing Operations: Markus Gemuend
Industry Information
Sector:
Industry:
Top Competitors
GlaxoSmithKline plc (gsk)
Novartis AG (nvs)
Sanofi (sny)
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?